Transcription of Q8(R2) - ich.org
{{id}} {{{paragraph}}}
Example: bankruptcy
Q8(R2) - ich.org
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE pharmaceutical development Q8(R2) Current Step 4 version dated August 2009 This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA. Q8(R2) Document History First Codification History Date Parent Guideline: pharmaceutical development Q8 Approval of the Guideline by the Steering Committee under Step 2 and release for public consultation. 18 November 2004 Q8 Approval of the Guideline by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies.
Pharmaceutical Development 2 i.e., quality should be built in by design. Changes in formulation and manufacturing processes during development and lifecycle management should be looked upon as
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
PHARMACEUTICAL DEVELOPMENT FOR, PHARMACEUTICAL DEVELOPMENT FOR MULTISOURCE (GENERIC) PHARMACEUTICAL, Pharmaceutical, Product Lifecycle Management for the Pharmaceutical, Development, Oracle Pharmaceutical, ICH Q10 Pharmaceutical Quality System, Pharmaceutical Development, Valuation Analysis in Pharmaceutical Licensing, DEVELOPMENT OF PAEDIATRIC MEDICINES: POINTS, Development of paediatric medicines: points to consider in pharmaceutical development, Stability Testing of Pharmaceutical Products